Articles tagged with: Clinical

Combination therapy improves survival in advanced kidney cancer

Posted in General News Published by Bethan Warman 13 February 2019

Combination therapy improves survival in advanced kidney cancer

A combination therapy has shown powerful anticancer responses in patients with a type of advanced kidney cancer in a new international phase III clinical trial (KEYNOTE-426). Treatment with the combination therapy resulted in significant increases in overall survival when compared with the current standard of care, and the findings will help to provide a vital new treatment option for patients with this disease.

BCI at the 60th ASH Annual Meeting

Posted in General News, BCI on the Road Published by Bethan Warman 14 January 2019

‘The premier event in malignant and non-malignant haematology’

BCI at the 60th ASH Annual Meeting

Researchers from our Centre for Haemato-Oncology attended the 60th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego on 1st-4th December 2018. The ASH Annual Meeting provides an invaluable opportunity to showcase the work being conducted here at the BCI and brings together professionals from all subspecialties of blood disease research.

Tackling the deadliest cancer type

Posted in General News Published by Bethan Warman 30 November 2018

Our lung cancer research

Tackling the deadliest cancer type

This month is Lung Cancer Awareness Month. Lung cancer is the third most common cancer in the UK, with 46,700 new cases diagnosed each year. Approximately 35,600 people lose their lives annually as a result of lung cancer in the UK, making it the most common cause of cancer-related mortality. Only 5% of those affected survive their cancer for 10 years or more in the UK, and this survival rate has not shown much improvement over the last four decades.

New phase 3 clinical trial using combination therapy extends survival in triple-negative breast cancer

Posted in General News, BCI on the Road, Publications Published by Bethan Warman 22 October 2018

New phase 3 clinical trial using combination therapy extends survival in triple-negative breast cancer

New research led by Barts Cancer Institute and St Bartholomew’s Hospital has provided new hope for people with an aggressive type of breast cancer. The phase 3 clinical trial has shown that by using a combination of immunotherapy and chemotherapy, the body’s own immune system can be tuned to attack triple-negative breast cancer, extending survival by up to ten months.

Immunotherapy shows promise for patients with metastatic triple-negative breast cancer

Posted in General News, Publications Published by Bethan Warman 17 October 2018

Immunotherapy shows promise for patients with metastatic triple-negative breast cancer

Immunotherapy has been shown to confer an encouraging survival benefit in patients with metastatic triple-negative breast cancer (mTNBC). The phase 1 clinical trial, led by Prof Peter Schmid, Centre Lead for BCI’s Centre for Experimental Cancer Medicine, is the first to report the long-term safety and efficacy of the drug for mTNBC, and may represent significant steps forward for treatment of this disease.

World Cancer Research Day 2018

Posted in General News Published by Bethan Warman 24 September 2018

World Cancer Research Day 2018

Today is World Cancer Research Day- a day dedicated to raising awareness of the importance of cancer research. Thanks to a united effort by researchers from around the world, cancer survival rates have doubled in the last 40 years, and 50% of those diagnosed with cancer now survive. To continue to improve these statistics, it is vital to identify new and more effective early detection methods and treatments that can improve the lives of those with cancer.

VOICE 2018: From bedside to bench

Posted in General News, Engagement Published by Bethan Warman 12 September 2018

VOICE 2018: From bedside to bench

Last week, BCI held the 2018 VOICE (Vision On Information, Confidence & Engagement) course- a study week that aims to take patient advocates from bedside to bench by providing an introduction to basic cancer biology, research terminology and study design. This unique course was developed by Independent Cancer Patients’ Voice (ICPV)- a patient advocate group led by patients for patients- to empower patient advocates and increase their confidence to get involved in the cancer conversation.

BCI at the 2018 ASCO Annual Meeting: Results from the PAKT and ABACUS trials

Posted in General News, Conferences, BCI on the Road Published by Bethan Warman 15 June 2018

BCI at the 2018 ASCO Annual Meeting: Results from the PAKT and ABACUS trials

Professors Peter Schmid and Thomas Powles attended this year’s ASCO Annual Meeting, which took place from 1st-5th June in Chicago. The Centre Lead of our Centre for Experimental Cancer Medicine (CECM), Prof Schmid, presented data from the PAKT trial- a trial investigating the addition of a novel drug called AZD5363 to a standard chemotherapy regimen as a treatment for triple-negative breast cancer (TNBC). Prof Powles of the CECM and Director of the Barts Cancer Centre, presented results from the ABACUS trial, which is investigating the efficacy and safety of a drug called atezolizumab administered prior to cystectomy in muscle invasive bladder cancer. The ABACUS trial was selected as one of the highlights of this year’s meeting.

London Pancreas Workshop 2018

Posted in General News, BCI Spotlight Articles, Events Published by Bethan Warman 11 May 2018

A forum for state-of-the-art clinical and basic research in pancreatic cancer

London Pancreas Workshop 2018

On Friday 4th May, BCI hosted the seventh London Pancreas Workshop, co-organised by Prof Hemant Kocher and our Director Prof Nick Lemoine, which attracted delegates from across Europe and America, with over 140 attendees in total. The biennial event is recognised as a forum for state-of-the-art clinical and basic research in pancreatic cancer.

The areas of focus for this year’s workshop were diagnostics, clinical trials and preclinical work for targeting pancreatic cancer. We heard a variety of interesting talks in these areas, delivered by researchers renowned in their fields.

This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.